News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

DGAP-News: Epigenomics AG / Key word(s): Bond/Issue of Debt
13.09.2021 / 13:24
The issuer is solely responsible for the content of this announcement.


Press Release

Epigenomics AG places maximum number of mandatory convertible bonds with a total volume of EUR 16.5 million

Berlin, September 13, 2021 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the “Company”) has successfully completed the placement of the subordinated non-interest-bearing mandatory convertible bond, which the Company’s Executive Board had resolved to issue with the approval of the Supervisory Board. The maximum volume of the mandatory convertible bond was placed in the aggregate principal amount of EUR 16,500,000.00. The mandatory convertible bond consists of 165,000 notes, which – subject to adjustments of the conversion price due to anti-dilution clauses – are convertible into 15,000,000 registered no-par value shares of the Company. Further details of the transaction were announced in the corporate news dated August 24, 2021. The gross proceeds from the issuance of the mandatory convertible bond amount to EUR 16,500,000.00.

As announced in the ad-hoc announcements of June 11, 2021, and August 20, 2021, the issuance of the mandatory convertible bond was secured by a back-stop agreement with Deutsche Balaton Aktiengesellschaft. In connection with this back-stop agreement, Deutsche Balaton has subscribed for notes in the aggregate principal amount of EUR 2,717,800.00.

Epigenomics AG plans to use the proceeds from the issuance of the mandatory convertible bond to finance its operations, in particular the further development of the blood-based colorectal cancer screening test Epi proColon Next-Gen. For this purpose, the Company plans to conduct a clinical study in the U.S.A., which is required to obtain approval for the test by the U.S. Food and Drug Administration (FDA).

The full terms and conditions of the mandatory convertible bond are available on Epigenomics AG’s website at

About Epigenomics
Epigenomics AG is a molecular diagnostics company focused on blood testing for the early detection of cancer. Based on its proprietary biomarker technology for the detection of methylated DNA, Epigenomics develops and markets blood tests for various cancer indications with high unmet medical need. Epigenomics’ lead product is the blood test Epi proColon(R) for the early detection of colorectal cancer. Epi proColon is approved by the U.S. Food and Drug Administration (FDA) and is marketed in the United States and Europe as well as other selected countries. HCCBloodTest, a blood test for the detection of liver cancer, have received the CE Mark for marketing in Europe.

For further information please visit

Epigenomics AG, Geneststrasse 5, 10829 Berlin
Tel +49 (0) 30 24345 0, Fax +49 (0) 30 24345 555, E-Mail:

Investor Relations
IR.on AG, Frederic Hilke, Tel +49 221 9140 970, E-Mail:


This press release as well as the information contained herein shall not constitute or be construed as an offer to sell or the solicitation of an offer to buy any securities of Epigenomics AG in the Federal Republic of Germany or any other jurisdiction, in particular where such offer or solicitation is prohibited or unauthorized, and does not replace the securities prospectus. Potential investors in partial bonds of the mandatory convertible bond 2021/2027 of Epigenomics AG are requested to inform themselves about such restrictions and to comply with them. An investment decision regarding the partial notes of the mandatory convertible bond 2021/2027 of Epigenomics AG may only be made on the basis of the securities prospectus approved by the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht – BaFin) on August 24, 2021, which has been published at The approval by BaFin should not be construed as an endorsement of the securities offered. Prospective investors should read the prospectus before making an investment decision in order to fully understand the potential risks and rewards of deciding to invest in the securities. The information contained in this document may not be distributed outside the Federal Republic of Germany, in particular not in the United States, to U.S. persons (as defined in Regulation S under the United States Securities Act of 1933) or to publications with a general circulation in the United States, unless such distribution outside the Federal Republic of Germany is required by mandatory provisions of applicable law. Any violation of these restrictions may constitute a violation of securities laws of certain countries, in particular the United States. Bonds of Epigenomics AG will not be publicly offered for sale outside the Federal Republic of Germany.

Forward-looking statements

This publication expressly or implicitly contains forward-looking statements concerning Epigenomics AG and its business. These statements involve certain known and unknown risks, uncertainties and other factors that may cause Epigenomics AG’s actual results, financial condition and performance to be materially different from any future results, performance or achievements expressed or implied by such statements. Epigenomics makes this announcement as of the date of this release and does not intend to update any forward-looking statements contained herein as a result of new information or future events or otherwise.


13.09.2021 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this